DBV Technologies is a clinical-stage biopharmaceutical company founded in 2002, developing immunotherapy product candidates utilizing a novel proprietary technology platform based on investigational epicutaneous immunotherapy, which aims at delivering biologically active compounds to the immune system through intact skin.

The most advanced product candidates are currently being developed for the treatment of food allergies. With this class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic children. Food allergies are an increasingly prevalent condition worldwide with no currently approved treatments.

DBV’s food allergies programs include ongoing clinical trials on Peanut and Milk allergies, and preclinical development on Egg allergy. DBV is also pursuing a human proof-of-concept clinical trial of Milk for the treatment of Eosinophilic Esophagitis and exploring potential applications of its platform in vaccines and other immune diseases.